Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — 10th Annual Australian Microcap Investment Conference 2019
23 slides from Anatara Lifesciences's conference presentation, Oct 23, 2019
Slide 1: ASX Release: Anatara Investor Presentation
ASX Release Anatara Investor Presentation For personal use only BRISBANE & MELBOURNE, 23rd October 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Mi
Slide 2: Australian Microcap Investment Conference
Australian Microcap Investment Conference For personal use only October 2019 Advancing gastrointestinal health
Slide 3: Disclaimer
2 Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, AC
Slide 4: Key Investor Message
3 Key Investor Message For personal use only More than ever, the world is looking for safe and effective solutions to gut health. The Anatara team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.
Slide 5: Corporate Fast Facts
4 Corporate Fast Facts Board of Directors: For personal use only Sue MacLeman ASX ticker code Dr Jane Ryan ANR Dr Tracie Ramsdale Dr David Brookes Management: Steve Lydeamore, CEO Dr Tracey Brown, CSO Share Price Market Capitalisation Dr Michael West, COO $0.22* $10.87 million* Product Development A
Slide 6: Investment highlights: multiple shots on goal
5 Investment highlights: multiple shots on goal For personal use only Human health asset, GaRP: • Aimed at restoring and maintaining gut health with excellent (pre-clinical in vitro and in vivo animal studies) data to date • Human clinical study initiation anticipated late 2019 • View to a partnerin
Slide 7: Need to combat antimicrobial resistance
6 Need to combat antimicrobial resistance For personal use only “Antimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.”’ Dr Tedros Ghebreyesus, Director-General, World Health Organisation (WHO) 2019 70% of bacteria globally h
Slide 8: Detach can help
7 Detach ® can help For personal use only Detach® increases survivability and provides health benefits to pre-weaning piglets • 15-20%5 of piglets born will die before weaning due to health issues including scour • Orally administered, non-antibiotic product for the control of scour in piglets • Nat
Slide 9: Detach Next Steps
8 Detach® Next Steps For personal use only • Secure international animal health partner(s) – by end FY 2020 – regulatory approval of Detach® in key overseas markets • opportunity to fast track registration in SE Asia – develop new formulations and administration methods for Detach® to expand utility
Slide 10: From animals to humans
For personal use only From animals to humans
Slide 11: Burgeoning microbiome market: our first targets
10 Burgeoning microbiome market: our first targets For personal use only Source: http://big.assets.huffingtonpost.com/2015_GutBacteriaA.png
Slide 12: IBS and IBD in a minute
11 IBS and IBD in a minute 11% >5m For personal use only IBS affects around 11% of With accelerating incidence, the global population6 IBD has an estimated >5million sufferers worldwide7 IBS costs more than $21 billion Total financial burden of IBD in the US annually in direct medical costs and alon
Slide 13: Profound impact on patients
12 Profound impact on patients For personal use only “Imagine a day where you fell ill from having eaten too much, then imagine that day lasts months at a time.” Australian IBS patient12 12 IBS Global Impact Report 2018 https://badgut.org/wp-content/uploads/IBS-Global-Impact-Report.pdf
Slide 14: Why a dietary supplement?
13 Why a dietary supplement*? The advantages of a dietary supplement regulatory strategy are: For personal use only Fewer or lower regulatory requirements than pharmaceuticals13 • Lower development cost • Lower development risk • Faster time to market Swift timeframe to partnering milestone Rapid ma
Slide 15: USA gastrointestinal health market
14 USA gastrointestinal health market For personal use only US $8b USA digestive remedies and GI supplement sales 8/10 US$5b Adults suffer annually OTC** digestive remedies 2018 15 from a digestive issue15 US$3b ↑ 11.9% GI* supplement sales 201816 OTC** digestive remedies over the past 5 years15 * G
Slide 16: Global consumer health market opportunity
15 Global consumer health market opportunity For personal use only US$5.7 billion Global probiotic supplement sales 17 Probiotic supplements Other GI supplements OTC digestive supplements Align® (P&G) sales Iberogast® (Bayer) sales Buscopan® (Sanofi) sales (U.S.) 2018: (Germany) 2018: (Global) 2018:
Slide 17: Primary underlying factors of IBS and IBD
16 3 primary underlying factors of IBS and IBD For personal use only
Slide 18: How are these addressed?
17 How are these addressed? Dietary modification For personal use only Probiotics – limited evidence for clinical efficacy Anti-inflammatory drugs – severe GaRP side effect profile No direct treatments with long term results *Gastrointestinal ReProgramming (GaRP) dietary supplement
Slide 19: Changing the game for IBS and IBD
18 Changing the game for IBS and IBD For personal use only GaRP dietary supplement • Regenerative, multi-component dietary supplement • Triple-targeted therapeutic approach • anti-adhesion • anti-inflammatory • mucosal regeneration • Dual targeted formulation, delivering components to where they can
Slide 20: Grounded in scientific evidence
19 Grounded in scientific evidence For personal use only Successful Proof of Concept Studies (February & October 2019) Demonstrated using industry-standard in vitro gut model
Slide 21: GaRP has been shown to…..
20 GaRP has been shown to….. • Address the dysbiosis of the microbiome For personal use only • Inhibiting the attachment and invasion of pro-inflammatory bacteria by >95% • Reduce gut inflammation • Reducing the production of pro-inflammatory proteins by >85% • Reducing colon inflammation and disrup
Slide 22: Anticipated Milestones
21 Anticipated Milestones For personal use only • Further data from preclinical in vivo animal studies is expected late 2019 • Pre-trial activities for a human clinical study in IBS patients have commenced, with a view to study initiation late 2019 • Anatara is exploring options to build marketing c
Slide 23: Contact Anatara Lifesciences Ltd
22 For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, CEO +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — 10th Annual Australian Microcap Investment Conference 2019 on 6ix